🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist




























Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Standalone Quarterly Results (in ₹ Crores)

Total Figures
QoQ Changes
Total Figures
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales38363933413741364643
Expenses29282923302830273236
Operating Profit9.107.209.859.29118.82118.96137.42
OPM %23.7720.1925.3628.5527.7323.9126.4625.2228.7517.25
Other Income1.101.351.191.411.851.581.882.062.081.82
Interest0.070.070.060.110.120.110.110.110.110.12
Depreciation0.590.630.620.520.640.780.790.720.740.83
Profit Before Tax9.547.841010139.511210148.30
Tax %23.2731.1223.9226.3423.3231.6527.8723.4829.1028.55
Net Profit7.325.407.887.429.606.518.547.79105.93
EPS in Rs16.5912.2517.8616.8021.7514.7519.3417.6623.0313.44

Standalone Profit Loss (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales105115123119109124137142152155
Expenses849198998997106109111115
Operating Profit21242520202730334040
OPM %20.3320.9620.3516.6118.1521.9822.2123.3326.6325.90
Other Income2.963.393.414.224.314.955.124.676.727.37
Interest0.410.410.390.530.470.430.370.270.450.45
Depreciation1.791.501.352.302.041.902.262.342.732.93
Profit Before Tax20252721223033354444
Tax %34.0431.8825.6729.6523.7525.3525.1326.1527.0226.36
Net Profit14172015172225263232
EPS in Rs30.9139.1344.8633.6937.4150.5255.2158.8772.6473.47
Dividend Payout %27.8824.0023.6425.0028.3624.7026.7225.9924.78

Standalone Balance Sheet (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital4.654.654.594.594.594.594.594.414.414.41
Reserves365057737594113118141167
Borrowings5.426.370.247.473.445.076.762.930.003.89
Other Liabilities12161618211819162021
Total Liabilities587677103104121143142165196
Fixed Assets12119.579.59121111101015
CWIP0.000.000.000.990.120.380.210.961.2440
Investments0.611.945.425.384.076.757.96111721
Other Assets4564628788104123119137121
Total Assets587677103104121143142165196

Standalone Cash Flows (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity7.829.95161315199.27178.1228
Cash from Investing Activity-0.27-9.771.00-11-2.88-19-1.202.62-0.58-17
Cash from Financing Activity-5.420.68-18-2.42-11-0.71-5.53-21-7.08-7.62
Net Cash Flow2.130.86-0.800.041.31-0.042.54-1.370.473.24

Documents

Presentations
Concalls
Reports
Presentations

No documents found!

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd (JENBURPH) is currently trading at 1,003.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally. The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards. Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally. In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.

Over the past 52 weeks, Jenburkt Pharmaceuticals Ltd has traded between a low of ₹944.00 and a high of ₹1,410.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jenburkt Pharmaceuticals Ltd has a market capitalization of approximately 440.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jenburkt Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.66 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 440.45 Cr, Jenburkt Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jenburkt Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jenburkt Pharmaceuticals Ltd is 13.66. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.